The old way isn't working

10+ years

To bring new gene therapies to market.

$250B+

R&D resources lost to failed clinical trials.

90% failure

Therapeutics almost never make it past clinical testing.

Imagine a different path.

One defined by speed, automation and simplicity.

ABYA is more than just a software.
‍
It’s the blueprint for the next generation of biotechnology.
‍
A future where gene therapies design, test, and validate themselves in silico.

Where safety and efficacy are proven through computation, not experimentation.

Where discovery, design and delivery lives in one ecosystem.

The new language of medicine.